Eyeing faster path for sickle cell drug, Peninsula biotech plots expansion — for a higher price

Less than a year after moving into one of South San Francisco's new biotech real estate developments, Global Blood Therapeutics Inc. will be moving again, nearly tripling its space as it shifts operations just a few yards away. Like any biotech company looking to move digs in a tight real estate market, Global Blood will pay top dollar to do so. Even as real estate developers add millions of square feet in South San Francisco alone, it is being snatched up quickly by large pharmaceutical companies…
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Source Type: news

Related Links:

The objectives of this study were to identify cases of hypereosinophilia in a tertiary pediatric medical center, determine clinical characteristics and disease associations, and estimate the incidence of hypereosinophilia in the hospital and geographic populations.MethodsA retrospective chart review included patients
Source: The Journal of Allergy and Clinical Immunology: In Practice - Category: Allergy & Immunology Source Type: research
Sickle cell disease (SCD) results from a unique mutation in the β-globin gene and is the most common genetic hemoglobinopathy. It is characterized by hemolytic anemia, painful vaso-occlusive crisis, and progressive organ failure, including nephropathy. Red blood cells (RBCs) in patients with SCD are subjected to constant endogenous and exogenous oxidative stres s, which in turn increase hemolysis and contribute to vasculopathies. A gradient of hemolysis among SCD patients influences the SCD phenotype.
Source: Kidney International - Category: Urology & Nephrology Authors: Tags: Nephrology Digest Source Type: research
Conclusion: There was no difference between VTE recurrence and choice of anticoagulation in SCD patients with VTE. Bleeding events were lower for DOACs compared to VKA or LMWH.Acta Haematol
Source: Acta Haematologica - Category: Hematology Source Type: research
Abstract BACKGROUND: Venous thromboembolism (VTE) is a recognized complication of sickle cell disease (SCD), yet the optimal pharmacologic anticoagulant is unknown. METHODS: A retrospective single-institution cohort study of patients with SCD complicated by first VTE from January 2009 through July 2017 was performed using ICD 9/10 codes. Data collected included the anticoagulant used, VTE recurrence, and incidence of bleeding. RESULTS: 109 patients with VTE were identified. SCD genotypes included HbSS in 92 (84%), HbSC in 13 (12%), and HbS-β+ thalassemia in 4 (4%). After the initial VTE event, 32 pa...
Source: Acta Haematologica - Category: Hematology Authors: Tags: Acta Haematol Source Type: research
CONCLUSION: Using NAAT for the detection of respiratory pathogens in adults presenting with SCD slightly improved the microbiological diagnostic of febrile ACS, although respiratory infections are not the main etiological factor. PMID: 31088757 [PubMed - as supplied by publisher]
Source: Medecine et Maladies Infectieuses - Category: Infectious Diseases Tags: Med Mal Infect Source Type: research
[Monitor] The Kabaka of Buganda Ronald Muwenda Mutebi II has injected shs494m in Sickle cell prevention and treatment campaign.
Source: AllAfrica News: Health and Medicine - Category: African Health Source Type: news
Purpose of review Asthma is common in children with sickle cell disease (SCD) and appears to be associated with increased morbidity. Providers caring for children with SCD have struggled with the question of whether asthma exists as a true comorbidity or whether certain aspects of the chronic inflammatory disease gives children with SCD an asthma-like phenotype. Recent findings Clinical signs and symptoms seen in children with asthma in the general population, such as wheezing, airway hyperresponsiveness, atopy, elevated leukotrienes, and abnormal lung function are seen in children with SCD both with and without a dia...
Source: Current Opinion in Pediatrics - Category: Pediatrics Tags: PULMONOLOGY: Edited by David N. Cornfield Source Type: research
Abstract PMID: 31097635 [PubMed - as supplied by publisher]
Source: Haematologica - Category: Hematology Authors: Tags: Haematologica Source Type: research
ckman E, Poirot C, Socié G, Société Française de Greffe de Moelle et de Thérapie Cellulaire Abstract Allogeneic stem cell transplantation remains the only curative treatment for sickle-cell anemia, but the place of myeloablative conditioning remains to be defined. The aim of the present study was to analyze long-term outcomes, including chimerism, sickle-cell anemia-related events and biological data (hemoglobin, reticulocytes, HbS%), and fertility, in a French series of 234 SCA-patients younger than 30 years who received (1988-2012) a matched-sibling-donor stem cell transplantat...
Source: Haematologica - Category: Hematology Authors: Tags: Haematologica Source Type: research
Recently saw a 50 something year old gentleman with supposed sickle cell disease who still had both native hips, no heart failure, no strokes, no CKD, or any other medical co-morbidities. I found all of that to be beyond abnormal given the low life expectancy and the typical disease burden of someone living that long with SCD. He is apparently a regular at our hospital presenting to the ER at least 5-6x/month and being admitted 1-2x/month and has been doing this for the last 3 years. He was... How often have you caught patients in a lie perpetuated for years?
Source: Student Doctor Network - Category: Universities & Medical Training Authors: Tags: Emergency Medicine Source Type: forums
More News: American Health | Biotechnology | Health Management | Sickle Cell Anemia